

Preventing VTE (Blood Clots) in Hospitals
Irish National Improvement Collaborative





Ouality Improvement Division


Why an improvement collaborative?

- Medication safety programme goal
 - Reduce patient harm with medication or its omission
 - High-risk medication

- Opportunity to reduce harm at scale
- Build on successes, share learning
 - Equip teams with QI skills



Venous Thromboembolism, VTE



- Blood clot (thrombus) forms
 within deep veins (DVT,
 Deep Vein Thrombosis)
- Can fragment and travel to lungs leading to Pulmonary Embolism (PE)

Hospital-acquired VTE

- Accounts for
 - 60-63% of all VTE
 - 10% of hospital deaths
 - 0.4-3.8% of public hospital budgets in Europe (OECD)
- □ 70% preventable by prophylaxis Geerts et al 2001 and 2004





Mum of five dies suddenly from blood clot a week after giving birth to triplets

12:47, 9 MAR 2016 UPDATED 13:29, 9 MAR 2016 BY RHIAN LUBIN Cassia Rott, 36, gave birth to triplets on January 29 but died suddenly a week later, leaving her husband Joe to raise their five children.

Enter your e-mail for our daily newsletter



Mother died nine days after routine surgery, inquest hears

Karen McCabe (46) suffered blood clot after undergoing procedure to remove varicose veins

O Thu, Feb 18, 2016, 19:04

Sports reporter Johnny Lyons was in 'severe pain' days before death

Today FM presenter had been recovering from a fall a month earlier, inquest told

Mon, Jan 30, 2017, 14:35 Updated: Mon, Jan 30, 2017, 14:37

Louise Roseingrave



Sports broadcaster Johnny Lyons was found dead at his apartment on August 19th 2015.



ey Drive, Lucan, Co Dublin, underwent radiofrequency ablation, a minimally invasive sive varicose veins at the Bons Secours Hospital in Dublin on August 6th, 2014.

mother of three died nine days after routine surgery on varicose gs, an inquest has heard.



Room for & promise of improvement

Three Irish hospitals in ENDORSE

- Surgical: 59% at risk, 64% received appropriate prophylaxis
- Medical: 43% at risk, 47% received appropriate prophylaxis
 - Murphy O et al. Ir Med J. 2012 May;105(5):140-3

□ 11 Irish acute hospitals in PREVENT-VTE

- 30% of at-risk adult medical in-patients received LMWH
 - Adamali H et al. Ir Med J. 2013 Nov-Dec; 106(10):302-5





Some Irish improvements

- Education, posters, guidelines and pre-printed prophylaxis box 39% appropriate to 57% (p<0.001)
- Education 48% to 63% (p=0.041)
- Medical admission proforma reminder -37.5% appropriate in 2006, 75% in 2009, 86% in 2012
- Drug chart with prompt to assess risk 38% to 89%
- Drug chart with VTE prophylaxis section 59-71%
- Computerised tool 92% risk-assessment







What and how?

Pre-collaborative

- Pilot project
- Literature review
- Advisory group
- Survey





Advisory Group


- Philip Crowley
- David Vaughan
- Olivia Sinclair
- Catriona O'Leary
- Teresa Donnelly
- Ciara Kirke
- Maeve Raeside
- John Fitzsimons
- Mary Browne


- Susan O'Shea
- Fionnuala Ní Áinle
- Jeremy Sargent
- Sean Tierney
- Sean Gaine
- Brian Cleary
- Oran Quinn
- Melissa Redmond
- Olive O'Connor


Which guidelines?


- National guideline in maternity; no others
- Hospitals use different guidelines, some had none
- For medical patients
 - ACCP recommend risk scoring e.g. Padua
 - NICE use a risk assessment all risks equal
 - Is NICE is simpler, easier to complete correctly?
 - Will NICE result in more patients being judged at risk?

Guidelines










Need to choose wisely

- Thromboprophylaxis of medical in-patients
 - Reduced PE (OR, 0.70 [CI, 0.56 to 0.87])
 - Total mortality (RR, 0.93 [CI, 0.86 to 1.00]; p=0.056)
 - Increased all bleeding (RR, 1.28 [CI, 1.05 to 1.56])
 - Increased major bleeding (OR, 1.61 [CI, 1.23 to 2.10])
 - Absolute reduction 3 PEs, absolute increase of 9 bleeding events of which 4 were major per 1000 patients treated with heparin
 - Lederle. Ann Intern Med. 2011;155:602-615

Improvement collaborative



Reference: Institute for Healthcare Improvement, Boston, MA, USA (www.ihi.org)






Hospital teams

- □ CEO, DONM, Chief Pharmacist and Clinical Director
- □ Sponsor management team/clinical support and champion
- □ Improvement team − 3 (e.g. doctor, nurse, pharmacist) − attend
 learning sessions, carry out day to day improvement work
- □ Wider project team − subject-matter, process and quality improvement expertise, e.g. haematologist, surgeon; QI coach...
- Defined local governance and reporting
 - Model for Understanding Success in Quality





What are we trying to accomplish?

- Prevent hospital-acquired VTE and harm from unnecessary prophylaxis by ensuring
- Appropriate* thromboprophylaxis prescribed and administered within 24 hours of admission for [hospital defined subset of] in-patients

*In line with hospital guidelines





How will we know that a change is an improvement?

Preventing VTE in Hospitals Improvement Collaborative Measurement Guide



1. Get a list (census) of your patient population


- a. What sub-group of adult in-patients are you looking at?
 E.g. all medical/all surgical/all post-partum, acute
- Define admission time, e.g. time medical/surgical team con assessment and decide patient is to be admitted, time elect an in-patient on iPIMS system etc
- Admitted in previous 7 days (if taking a weekly sample) or 1 fortnightly sample), admission greater than 24 hours. You n

VTE risk assessment and prophylaxis data collection form. V3

Date						
Fortnight ending Friday						
Patient group	Medical □	Orthopaedio	c 🗆	Surgical (non-ortho)		
	Post-partum 🗆	Pregnant in-patient		Other 🗆		
Guidelines used	NICE Pa	dua 🗆 🛮 Çaprir	ji□ ACCP I	Local 🗆 Other 🗅		
Patient reference number				•		
At risk of VTE?	Low risk 🗆	At risk (/H	igh risk) 🛘	Medium risk 🛚		
Bleeding risk?	No 🗆	Yes 🗆	Not asse	Not assessed as not applicable		
Contraindication to stockings?	No 🗆	Yes 🗆	Not asse	Not assessed as not applicable		
Renal impairment (GFR below th	Normal	Normal 🗆 Renal impairment 🗆 Not kn				
dose reduction in your guidelines						
Weight?	Normal (50-10	0 kg) 🗆	High (ove	er 100 kg) 🗆		
	Low (weight ur	nder 50 kg) 🛘	Not know	wn 🗆		
The appropriate	LMWH/Hepari	in 🗆	No mechani	cal compression		
thromboprophylaxis, for this			Compression stockings			
patient should be	Drug Dose Fre	quency	Intermittent compression device			

A	D	E	G		J	L	N	P		
Hospital										
Name	Version 4	L	Į							
			ĺ							
	Fortnight			Local				Renal		
	ending			patient				impairment (dose		
Date collected	(DD/MM/YYYY)		Guidelines	reference				reduction needed		
(DD/MM/YYYY)	Friday	Patient group	used	number	At risk of VTE?	Bleeding Risk?	Contra-indication to stockings	with your	Weight	
	30/09/2016									
	30/09/2016									
	30/09/2016									
										Lo





What changes were tested?

- Reminders, preprinted prescriptions
- □ Risk assessment & prophylaxis guidelines
- □ Risk assessment forms
- □ Information, education, staff engagement, awareness
- □ Patient engagement, information, awareness
- □ Governance, leadership, reporting, feedback...







What did we achieve?


Demographics

- Participation from 27 hospitals, accounting for 77% of adult acute in-patient discharges
- □ Data from 22 of these on QlikView, n=2260
- Additional attendance from 6 hospitals
- Most hospitals have not yet fully implemented all planned changes






Processes and reliability




More appropriate heparins








More appropriate compression








More appropriate prophylaxis








Special cause variation





Mean appropriateness now 79%







What does this mean to patients?

- In the hospitals in the collaborative
- □ In the patient groups they're working with


35,000 more patients will receive appropriate VTE prophylaxis in the next year

□ 500 fewer blood clots? tbc






Heparin / LMWH





Compression






Improvements for medical patients




Surgical non-orthopaedic








Post-partum high appropriateness







Orthopaedics high appropriateness





What have we learned?

Dramatic improvement vs not

- □ It takes time: 507 hours vs 301 hours, 60% on testing and implementing changes, education etc
- Engaged and educated staff and patients more
- Had VTE protocol
- □ Had or tested preprinted Rx or prompts
- □ Had or introduced routine pharmacist check





Key learning

- Multi-faceted interventions most effective, including having a VTE protocol, prompts/alerts and education
- Helpful
 - Collaborative, pharmacist leadership, teamwork,
 consultant and clinical director support, hard work
- Challenges
 - TIME



Can you risk assess without a form?

□ Form available in 7 hospitals (n = 870)

- 34% completed; 73% appropriate prophylaxis
- 67% not completed; 71% appropriate prophylaxis
- Appropriateness of prophylaxis is not associated with whether form is filled in or not (Fisher's exact, p=0.48)
- Doctor preference not to fill in a form





Form conclusions

- Need an agreed hospital VTE protocol
- Needs to be accessible
- Do not recommend a form (unless proven in that hospital to be filled in and increase appropriateness)
- Consider pre-printed prescription(s) with a box to tick to indicate assessed

VTE Prophylaxis Protocol Template – Adult In-Patients < Modify for local use>

Assess all patients within 24 hours, repeat regularly and if clinical condition changes

Step 1: VTE risk assessment	Medical score	Surgical/trauma risk factor	Local decision where guidelines recommendations differ. Nedical scores in brackets are based on relative risk, but are not in the original Padua Prediction Score.	Medical score	Surgical/taun risk factor				
Surgical: Surgery/anaesthesia 90 mins or greater, or to pelvis or lower limb 60 mins or greater ¹									
Surgical: Acute surgical admission with inflammatory cond	ition or intr	ra-abdominal	condition ¹						
Immobility expected for at least 3 days ¹⁻⁴ (confined to bed +/- bathroom ^{2,8})	3		Ischaemic stroke ¹⁻⁴ (discuss with stroke team) or Acute MI ¹⁻⁴	1					
Active cancer or treatment (chemo-or radiotherapy within 6 months or metastases) ¹⁻⁴	3		Acute infection ¹⁻⁴ or Acute or chronic inflammatory disorder ¹⁻⁴	1					
Previous DVT/PE 1-4	3		Local decision: Aged 70 or over ²³ or 60 or over ¹	1					
Thrombophilia ¹⁻⁴	3		Local decision: Surgery in previous 30 days 23	2					
Taking oestrogen-containing contraceptive or HRT 1-4	1		Local decision: Pregnant or up to 6 weeks post-partum1.4	(3)					
BMI 30 or greater (obese) ¹⁻⁴	1		Local decision: Central venous catheter ⁴	(3)					
Heart or respiratory failure ¹⁻⁴	1		Local decision: Varicose veins ⁴ with phlebitis ¹	(1)					
			High risk: Surgical: Any risk factor; Medical:	Score 4	or greater				

Step 2: Bleeding risk assessment (any risk factor below = contra-indication to LMWH / heparin)					
Active bleeding 12	Epidural or spinal or lumbar puncture in last 4 hours or expected in next 12 hours 14				
Platelets less than 50 x 10 ⁹ /L ³ (or local decision: 75 x 10 ⁹ /L ³)					
Bleeding disorder, e.g. haemophilia Acquired bleeding disorder e.g. liver failure with PT over 15 13	Undergoing procedure with high bleeding risk, e.g. neurosurgery, spinal or eye surgery 1,8				
Acquired bleeding district e.g. liver failule with F1 over 15	History of Heparin-Induced Thrombocytopaenia (HIT): Contact haematology or pharmacy				
Acute stroke (discuss with stroke team) 13	Already receiving anticoagulant at therapeutic levels/dose				
Blood pressure 230 systolic or 120 diastolic ¹³ or greater	e.g. warfarin, dabigatran, rivaroxaban, edoxaban, apixaban, heparin, enoxaparin: No additional prophylaxis				



Step 3: Recommended prophy hip replacement, total knee rep			; e.g. until low-risk for VTE on r irgery for cancer)	isk assessment, until discharged	, or prolonged e.g. post-total			
All patients Adequate hydration, early mobilisation, leg exercises								
All surgical patients (or at-risk s	urgical patients)	Mechanical compression: Anti-embolism stockings*+/- intermittent pneumatic compression devices / foot pumps *Do not use in severe peripheral vascular disease, severe dermatitis, massive leg oedema, leg deformity, peripheral neuropathy, recent skin graft, allergy to fabric or acute stroke.						
High-risk medical (score 4 or gre with C/I to heparins	eater)							
	Weight 50-100 over 30 mL/mi	-	Weight 101-150 kg	Weight less than 50 kg	GFR less than 30 mL/min			
High-risk medical (score 4 or greater), no C/I	Tinzaparin 4500 units ⁵ or enoxaparin 40 mg once daily ⁵		Consider tinzaparin 4500 units bd	Consider tinzaparin 3500 units	Heparin 5000 units twice daily			
High-risk surgical (any risk factor), no C/I			or enoxaparin 40 mg bd	or enox aparin 20m g once daily	or Tinzaparin 3500 units daily (caution)			
Moderate-risk surgical (local decision: delete if no moderate- risk category)	Tinzaparin 3500 units ⁵ or enoxaparin 20 mg once daily ⁵		Consider tinzaparin 4500 units once daily or enoxaparin 40 mg once daily		or enoxaparin 20 mg daily ^s (contra-indicated in GFR less than 15 mL/min ⁵)			
Low-risk medical (score 3 or lower) or Low-risk surgical (no risk factor)	No heparin or low molecular weight heparin Medical patients: no mechanical compression unless patient is high-risk with contra-indication to heparins Surgical patients: localdecision: mechanical compression in at-risk or all surgical patients							

Step 4: Prescribe appropriate prophylaxis on medication record

- 1. Venous thromboembolism: reducing the risk (NICE Clinical Guideline 92); January 2010
- 2. Barbar S et al. ...The Padua Prediction Score. J Thromb Haemost 2010; 8:2450-7
- 3. Kahn SR et al. Chest 2012; 141, 2 Suppl. (ACCP 9th Edition)

- 4. SIGN guideline 122; December 2010
- 5. Summaries of Product Characteristic, www.hpra.ie






Guidelines – what we found

- Does guideline affect % at risk?
 - 73% at risk with NICE
 - □ 67% at risk with Padua
 - Yes, fewer judged at risk with Padua (p=0.01)
- □ Is NICE easier to use, i.e. higher appropriateness?
 - 67% appropriate with NICE
 - 62% appropriate with Padua
 - No, similar appropriateness (p=0.06)



Regular Presci	riptions			Year			Dav &	Month	DD/MM			
(Prescribe antimicrobials in antimicrobials section)												
Prescriber circle	time or enter	variable time i	n second colum	in —		7						
Pharmacological Thromboprophylaxis (name) Prescribe only if indicated and patient h			nt has no contraindications	6	,							
			8									
Route		Dose Frequency & Prescriber c		escriber circle time								
					10							
Special Instructions Reviewed		Reviewed By		12								
Prescriber Sig		Reg No	Date Date		14	V			K	5		
rescriber sig neg no bate			18									
Stop Date	Reason		Signature									
			22									
Mechanical Thromboprophylaxis (name) Prescribe only if indicated and patient has no contraindications			6									
					8							
Special Instructions Rev		Reviewed By										
Measure to select appropriate size				10								
Assess fit, compliance and skin integrity daily and sign			12									
		100	Date	0.14.0.10	12	_						
			14	W				6				
Prescriber Sig		Reg No	Date		40			44			1	
Stop Date Reason Signature			18									
					22							

níse Sláinte outive



Quanty improvement Division



Next steps

Next steps

- □ Report, recommendations, toolkit
 - Launch, distribution, on website June 2018
- Patient information cards
 - With Thrombosis Ireland, piloted in 7 hospitals
- Key performance indicator
 - Hospital-acquired in-hospital VTE





Learning from collaborative

Huge commitment in hospitals to safer patient care

 Challenges – resources, guideline, standardising and merging data, 27 sites, duration

□ Fabulous results with a real impact on patients

to share to share



Thank you to teams from

- □ Beaumont, Cappagh, Coombe, Cork, Letterkenny
- Mallow, Mater, Mayo, Mercy, Mullingar
- Naas, NRH, NMH Holles Street, Drogheda
- Portlaoise, Roscommon, Rotunda, SIVUH
- South Tipperary, Loughlinstown, St James's
- St John's, St Luke's Kilkenny, St Vincent's
- Tallaght, Tullamore, Wexford






Thank you

- Philip Crowley, Maeve Raeside, Alison Cronin, Larraine Gilligan
- David Vaughan, Olivia Sinclair, Melissa Redmond, Philip Crowley, Ann Marie and Thrombosis Ireland, Johnny McHugh, Brian Cleary, Paul Rafferty, Audrey Purcell, Oran Quinn, John Fitzsimons, Mary Browne
- Advisory group
- □ Anne-Marie Cushen, Nuala Doyle, Peter Branagan & Beaumont
- Eoin Darcy, Jennifer Veale, Malcolm Cooke



www.hse.ie/e ng/about/ who/qid











www.safermeds.ie

Twitter@ciarakirke

Email: safermeds@hse.ie